Mar 12, 2007 – Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis.
Mar 2007 – Primary Endpoint Met
Announcement Date: March 12, 2007
Mar 12, 2007 – Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis.